ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
3.750
+0.180 (5.04%)
Nov 21, 2024, 12:21 PM EST - Market open

ImmuCell Statistics

Total Valuation

ImmuCell has a market cap or net worth of $29.37 million. The enterprise value is $39.92 million.

Market Cap 29.37M
Enterprise Value 39.92M

Important Dates

The last earnings date was Wednesday, November 13, 2024, after market close.

Earnings Date Nov 13, 2024
Ex-Dividend Date n/a

Share Statistics

ImmuCell has 7.83 million shares outstanding. The number of shares has increased by 1.57% in one year.

Current Share Class 7.83M
Shares Outstanding 7.83M
Shares Change (YoY) +1.57%
Shares Change (QoQ) +4.54%
Owned by Insiders (%) 33.42%
Owned by Institutions (%) 14.75%
Float 4.71M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 1.19
Forward PS n/a
PB Ratio 1.20
P/TBV Ratio 1.07
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.67
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.11, with a Debt / Equity ratio of 0.59.

Current Ratio 3.11
Quick Ratio 1.37
Debt / Equity 0.59
Debt / EBITDA 21.73
Debt / FCF n/a
Interest Coverage -17.96

Financial Efficiency

Return on equity (ROE) is -14.54% and return on invested capital (ROIC) is -4.04%.

Return on Equity (ROE) -14.54%
Return on Assets (ROA) -3.85%
Return on Capital (ROIC) -4.04%
Revenue Per Employee $301,747
Profits Per Employee -$48,241
Employee Count 79
Asset Turnover 0.54
Inventory Turnover 2.28

Taxes

In the past 12 months, ImmuCell has paid $5,368 in taxes.

Income Tax 5,368
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -24.39% in the last 52 weeks. The beta is 0.57, so ImmuCell's price volatility has been lower than the market average.

Beta (5Y) 0.57
52-Week Price Change -24.39%
50-Day Moving Average 3.61
200-Day Moving Average 4.36
Relative Strength Index (RSI) 50.20
Average Volume (20 Days) 14,495

Short Selling Information

The latest short interest is 4,009, so 0.05% of the outstanding shares have been sold short.

Short Interest 4,009
Short Previous Month 8,184
Short % of Shares Out 0.05%
Short % of Float 0.09%
Short Ratio (days to cover) 0.23

Income Statement

In the last 12 months, ImmuCell had revenue of $23.84 million and -$3.81 million in losses. Loss per share was -$0.49.

Revenue 23.84M
Gross Profit 6.89M
Operating Income -2.74M
Pretax Income -3.89M
Net Income -3.81M
EBITDA -49,834
EBIT -2.74M
Loss Per Share -$0.49
Full Income Statement

Balance Sheet

The company has $3.81 million in cash and $15.53 million in debt, giving a net cash position of -$11.72 million or -$1.50 per share.

Cash & Cash Equivalents 3.81M
Total Debt 15.53M
Net Cash -11.72M
Net Cash Per Share -$1.50
Equity (Book Value) 26.41M
Book Value Per Share 2.99
Working Capital 9.42M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$362,117 and capital expenditures -$350,853, giving a free cash flow of -$712,970.

Operating Cash Flow -362,117
Capital Expenditures -350,853
Free Cash Flow -712,970
FCF Per Share -$0.09
Full Cash Flow Statement

Margins

Gross margin is 28.92%, with operating and profit margins of -11.49% and -15.99%.

Gross Margin 28.92%
Operating Margin -11.49%
Pretax Margin -15.96%
Profit Margin -15.99%
EBITDA Margin -0.21%
EBIT Margin -11.49%
FCF Margin -13.02%

Dividends & Yields

ImmuCell does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -1.57%
Shareholder Yield -1.57%
Earnings Yield -13.51%
FCF Yield -2.53%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 4